E
Sonoma Pharmaceuticals, Inc. SNOA
$2.76 $0.769938.69%
Recommendation
Sell
Prev Close
$1.99
Volume
32,358,933
Avg Vol (90D)
223,210
Market Cap
$3.22M
Dividend & Yield
--
52-Week Range
$1.90 - $9.37
P/E (TTM)
--
EPS (TTM)
-$3.96
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 25% Lower
3/8/2025 - Simply Wall St
Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando
2/26/2025 - GuruFocus
Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando
2/25/2025 - Accesswire
Financial Analysis: Sonoma Pharmaceuticals (NASDAQ:SNOA) and BrainsWay (NASDAQ:BWAY)
2/18/2025 - Ticker Report
Sonoma Pharmaceuticals Third Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
2/7/2025 - Simply Wall St
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results
2/6/2025 - GuruFocus
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results
2/5/2025 - Accesswire
Sonoma Pharmaceuticals (SNOA) Stock Surges Amid Industry Decline
1/28/2025 - GuruFocus
Sonoma Pharmaceuticals (NASDAQ:SNOA) Shares Cross Above 200-Day Moving Average - Here's Why
1/4/2025 - Ticker Report
Sonoma Pharmaceuticals (SNOA) Stock Surges Amid Market Fluctuations
12/9/2024 - GuruFocus
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for ...
12/5/2024 - GuruFocus
Sonoma transitions first products to new EU MDR requirements
12/5/2024 - TipRanks Financial Blog
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices
12/5/2024 - Accesswire
Sonoma Pharmaceuticals (SNOA) Stock Declines Amid Market Activity
12/3/2024 - GuruFocus
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock
11/27/2024 - Zacks Investment Research
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product ...
11/22/2024 - GuruFocus
Sonoma Pharmaceuticals announces relaunch of dermatology, eye care lines
11/21/2024 - The Fly
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States
11/21/2024 - Accesswire
Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
11/12/2024 - Simply Wall St
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel
11/11/2024 - Accesswire
FDA grants Sonoma 510(k) approval for Microdacyn Hydrogel
11/11/2024 - TipRanks Financial Blog
Sonoma Pharmaceuticals GAAP EPS of -$0.59, revenue of $3.6M
11/8/2024 - SeekingAlpha.com: All News
Sonoma Pharmaceuticals reports Q2 (59c) vs ($5.75) last year
11/7/2024 - The Fly
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results
11/7/2024 - Accesswire
Income Statement
Total Revenue (TTM)
$13.97M
EBITDA (TTM)
-$4.32M
EBIT (TTM)
-$4.46M
Net Income (TTM)
-$3.75M
Balance Sheet
Total Assets (Q)
$13.67M
Total Debt (Q)
$119.00K
Total Liabilities (Q)
$8.80M
Book Value Per Share (Q)
$3.01
Cash Flow
Cash from Operations (TTM)
$159.00K
Cash from Investing (TTM)
-$15.00K
Cash from Financing (TTM)
$3.41M
Net Change in Cash (TTM)
$2.83M
Filings
Filing Date
Wednesday, February 5, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Jun 16 and 20 (est)
Price History
Loading...
Beta
1.49
7-Day Total Return
25.45%
30-Day Total Return
-2.82%
60-Day Total Return
-5.80%
90-Day Total Return
-7.69%
Year to Date Total Return
2.99%
1-Year Total Return
-10.39%
2-Year Total Return
-87.10%
3-Year Total Return
-95.16%
5-Year Total Return
-97.25%
52-week Low
Mar 07, 2025 - $1.90
52-week High
Jul 11, 2024 - $9.37
Valuation
Market Cap
$3.22M - Nano Cap
Enterprise Value
-$1.90M
Price/Sales (TTM)
0.21
Price/Book (Q)
0.66
Dividends and Shares
Shares Outstanding
1.46M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
sonomapharma.com
Phone Number
800 759 9305
Address
5445 Conestoga Court
Boulder, CO 80301
Country
United States
Year Founded
1999
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions... more
NASDAQ 03/10/2025 2:19PM Eastern Quotes delayed
Weiss Ratings